Blood-brain barrier integrity decreases with higher blood

pressure, a 7T DCE-MRI study

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background

 Blood-brain barrier (BBB) integrity is presumed to be impaired in hypertension, resulting from cerebral endothelial dysfunction. Hypertension antedates various cerebrovascular diseases, such as cerebral small vessel disease (cSVD), and is a risk factor for developing neurodegenerative diseases for which BBB disruption is a preceding pathophysiological process. In this study, we investigated the relation between hypertension, current blood pressure and BBB leakage in human subjects.

Methods

BBB leakage was determined in twenty-two patients with hypertension and nineteen

37 normotensive controls, age- and sex-matched (median age [range]: 65[45-80] years, 19 males),

using a sparsely time-sampled contrast-enhanced 7 Tesla MRI protocol. Structural cSVD

markers were visually rated. Multivariable regression analyses, adjusted for age, sex,

cardiovascular risk factors and cSVD markers, were performed to determine the relation

between hypertension status, systolic and diastolic blood pressure (SBP and DBP), mean

arterial pressure (MAP), drug treatment, and BBB leakage.

Results

Both hypertensive and normotensive participants showed mild scores of cSVD. BBB leakage

did not differ between hypertensive and normotensive participants, however was significantly

higher for SBP, DBP and MAP in the cortex, and DBP and MAP in the grey matter.

Effectively treated patients showed less BBB leakage than those with current hypertension.

Conclusion

BBB integrity in the total and cortical grey matter decreases with increasing blood pressure,

but is not related to hypertension status. These findings show that BBB disruption already

occurs with increasing blood pressure, before the presence of overt cerebral tissue damage.

Non-standard Abbreviations and Acronyms

- BBB blood-brain barrier
- cSVD cerebral small vessel disease
- DBP diastolic blood pressure
- DCE-MRI dynamic contrast enhanced magnetic resonance imaging
- GM grey matter
- MAP mean arterial pressure
- PVS perivascular spaces
- 87 ROI region of interest
- SBP systolic blood pressure
- TE echo time
- TR repetition time
- VIF vascular input function
- WM white matter
- WMH white matter hyperintensities

-
-
-
-
-
-
-
-
-
-

Introduction

 Hypertension is a highly prevalent condition, and its incidence increases in an aging 107 population.¹ In addition to the heart and kidneys, the brain is highly susceptible to high blood pressure, which consequently may result in neurological diseases, such as stroke and 109 dementia.² Hypertension causes vascular remodelling, which includes both structural and functional alterations of the vessel walls. Over time, these changes lead to endothelial dysfunction and to breakdown of the blood-brain barrier (BBB), with a detrimental effect on 112 the neuronal microenvironment and brain health. $3,4$ The BBB is a highly specialized structure in the cerebral vessel walls and preserves the biological homeostasis of the central nervous system through selective supply of nutrients to 115 the brain tissue and removal of waste products.⁵ Loss of BBB integrity increases the permeability of this barrier, and thereby allows neurotoxins to accumulate in the brain tissue. Although hypertension is assumed to have a negative effect on BBB integrity, the precise pathophysiology has not yet been elucidated. Potentially, vascular oxidative stress and inflammation lead to dysfunction of endothelial cells and degeneration of pericytes, 120 consequently resulting in a disrupted BBB.³ A large number of studies have investigated BBB impairment and hypertension in animal studies and found an increased permeability in several 122 regions for hypertensive models.⁶ Others reported subtle BBB impairment in human patients 123 with disorders such as preeclampsia, cerebral small vessel disease (cSVD), and dementia.⁷⁻¹⁰ While it is often assumed that hypertension leads to BBB disruption, the relation of hypertension or high blood pressure and BBB permeability has not yet been investigated explicitly in human subjects. The most commonly used technique to measure BBB integrity is dynamic contrast-enhanced

(DCE) MRI. This method uses the intravenous administration of a paramagnetic contrast

agent, which is subsequently followed over time by acquiring a continuous series of MRI

Data availability

 The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study population

 Between July 2019 and July 2021, 23 patients with essential hypertension and 20 normotensive, healthy controls were included, matched on age and sex. The patients with essential hypertension were recruited from the outpatient internal medicine clinic of the Maastricht University Medical Center, The Netherlands, and through a recruitment website 150 (hersenonderzoek.nl). Essential hypertension was defined as a mean blood pressure of ≥ 135 151 mmHg systolic or \geq 85 mmHg diastolic, or both, when measured for 30 minutes with an automated blood pressure monitor. Additionally, participants who took antihypertensive medication were also defined as hypertensive. The recruitment of healthy controls took place via advertisements in the local newspaper, in the hospital, and on a recruitment website

measurement. The arm which acquired the highest blood pressure was used for the subsequent

measurements every 5 minutes during 30-45 minutes. Throughout this time, the participant

- was kept seated solitary in the room, and was instructed to stay awake. To obtain the blood
- pressure characteristics, the last five measurements were averaged and used in the data

 analysis, yielding systolic and diastolic blood pressure (SBP and DBP, respectively), and mean arterial pressure (MAP).

-
- *MRI*

 Brain images were acquired with a 7 Tesla MRI (Magnetom, Siemens Healthineers, Erlangen, Germany) using a 32-channel phased-array head coil. Dielectric pads were placed on both sides of the participant's neck, proximal to the temporal lobes, for improvement of B1+ field homogeneity across the brain. Anatomical and DCE-images were acquired. The DCE- protocol consisted of quantitative precontrast 3D T1 mapping using a Magnetization-Prepared 188 2 Rapid Acquisition Gradient Echo (MP2RAGE) sequence (TR/TE = $5000/2.47$ ms, TI_1/TI_2 = 2700/900 ms, cubic voxel size = 0.7 mm, acquisition time = 8:00 min:s), followed by a 3D fast gradient echo T1-weighted perfusion (volumetric interpolated brain examination, VIBE) 191 sequence (TR/TE = $3.7/1.3$ ms, cubic voxel size = 2.0 mm, acquisition time = 2.47 min:s). After the first three volumes were acquired, the contrast agent (1.0 molar Gadobutrol, 3 mL for each participant) was injected with an infusion rate of 0.3 mL/s followed by a saline flush 194 (20 mL). Finally, two postcontrast T1 maps (TR/TE = $4000/2.32$ ms, TI₁/TI₂ = 2700/900 ms, 195 cubic voxel size $= 1.2$ mm, acquisition time $= 4:16$ min:s) were acquired, of which the first postcontrast T1 map was acquired immediately after the dynamic perfusion scan series and the last T1 map was acquired approximately 25 minutes after the start of CA injection. More details about the scan parameters and this protocol are reported in Table S1 and Kerkhof et al. $(2021).$ ¹¹ For optimal segmentation of grey matter (GM) and white matter (WM), a T2- weighted fluid–attenuated inversion recovery (FLAIR) sequence (TR/TE/TI = 8000/303/2330 ms; cubic voxel size: 1 mm, acquisition time: 6:59 min:s) was acquired in between the two postcontrast T1-maps. Additionally, for the rating of microbleeds and perivascular spaces (PVS), a susceptibility weighted imaging (SWI) sequence was acquired before contrast

administration, and T2-weighted images were acquired after contrast administration,

respectively.

Image analysis

 Preprocessing of the quantitative T1 maps consisted of bias field correction, skull stripping and gradient distortion correction. To correct for head displacements, all acquired images were spatially registered to the same reference image, which was the first postcontrast T1 map. Subsequently, GM and WM were automatically segmented using the precontrast T1 and 212 FLAIR images as input (FreeSurfer version $6.0.5$).¹² The segmentations were visually verified, and manually corrected when required. This resulted in four tissue regions of interest (ROI): total GM and total WM, cortical and deep GM). The subject-specific vascular input function (VIF) was derived from an ROI manually delineated in the superior sagittal sinus. The leakage maps were determined by applying the graphical Patlak approach to the concentration time-courses of each brain tissue voxel and the VIF, resulting in a Patlak plot, 219 in which the slope represents the BBB leakage rate, K_i [min⁻¹], and the intercept yields the 220 blood plasma volume fraction, v_p [-1.¹³ Per ROI, the mean K_i and v_p of all voxels within each ROI were calculated and used as physiological measures. Outlier correction was performed by considering the K_i and v_p values in these ROIs located in the 95% confidence interval.¹¹ All data analyses were performed using custom-made code in the Matlab programming environment (2019b, 9.2.0; Mathworks, Nattick, MA, USA). *cSVD rating*

Four cSVD-markers, i.e., white matter hyperintensities (WMH), lacunar infarcts, microbleeds

228 and MRI-visible PVS, were visually rated by one trained neuroscientist (MvdK: >2 years of

229 experience) under supervision of an experienced neuroradiologist (AAP: >20 years of 230 experience) and were combined into a global cSVD-score per participant.¹⁴ The WMH load 231 was rated using the Fazekas scale.¹⁵ When (early) confluent deep white matter 232 hyperintensities were present (Fazekas score 2 and 3) or irregular periventricular 233 hyperintensities which extended into the deep white matter (Fazekas score 3), one point was 234 assigned to the global $cSVD$ -score.¹⁴ Furthermore, one point was assigned when 1 or more 235 asymptomatic lesions, i.e., lacunar infarcts, were present.¹⁶ Another point was assigned when 236 1 or more microbleeds were present in the basal ganglia, since these were associated with 237 hypertension.¹⁶ Lastly, PVS were rated in the basal ganglia, as these have also been shown to 238 be associated with hypertension.^{17,18} The PVS score was established in the slice with the 239 highest number of PVS, and graded in four groups: $0: \leq 10$, 1: 11-25, 2: 26-40, 3: ≥ 41 PVS, 240 as previously published.¹⁹ A last point was assigned to the cSVD-score if moderate to 241 extensive PVS (score 1-3) were present. These points combined could yield a maximum 242 cSVD-score of 4 points.

243

244 *Statistics*

 To examine the differences in characteristics between hypertensive patients and controls, Pearson chi-square or Fisher's exact tests were applied for categorical variables when appropriate. For continuous variables independent Student's *t*-tests were performed. Outliers were defined as a data point with a deleted studentized residual higher than 3.5, and Cook's distance higher than 1.

250 First, we set out to determine the association between K_i or v_p in the ROIs (i.e., total GM, total WM, deep GM, cortical GM) with hypertension status by performing multivariable linear regression analyses, corrected for age and sex. Additionally, multivariable linear regression analyses corrected for age and sex were applied to investigate the relation between the

254 measured blood pressure characteristics – SBP, DBP and MAP – and the K_i and v_p in the brain ROIs. Furthermore, these analyses were repeated while alternately adjusting for relevant cardiovascular risk factors, which are BMI, alcohol use, history of smoking, and hematocrit level. Intake of antihypertensive medication and cholesterol lowering medication was also considered alternately in the regression analyses. Lastly, to study the potential influence of cSVD on the associations, the analyses were adjusted by total cSVD score. An additional post-hoc analysis was performed to explore the difference in leakage measures between the subgroups of hypertensive patients, which were based on the measured blood pressure on the day of the MRI-scan, and their blood pressure medication intake. This resulted in three subgroups: NT+: patients who had normal blood pressure levels, using 264 antihypertensive medication $(n=12)$, HT-: patients with high blood pressure, without using 265 antihypertensive medication $(n=5)$, and HT+: patients with high blood pressure, despite of using antihypertensive medication (n=5). To explore the between-group differences, ANOVA with post-hoc Tukey tests were performed. A *P*-value < 0.05 was considered statistically significant. All statistical analyses were

conducted using SPSS (version 28.0, Chicago, IL).

Results

272 The group characteristics of the hypertensive patients ($n = 22$ with a mean age of 66 years of 273 whom 64% are female) and the controls ($n = 19$ with a mean age of 62 years, of whom 42% are female) who were included for the final analysis are listed in Table 1. One control participant and one hypertensive patient were identified as outliers in terms of leakage rates and therefore excluded from further analysis. SBP was found to be significantly higher for the hypertensive patients than for the controls. No significant differences in blood pressure measures, age, sex, cardiovascular risk factors, blood measures, or cSVD scores were found.

282 The K_i in hypertensive patients did not significantly differ from the K_i in healthy controls,

283 while adjusting for age and sex (Table 2). In contrast, v_p was significantly higher for

284 hypertensive patients in all GM ROIs and showed a comparable trend for the entire WM.

285 Positive significant relations of *Kⁱ* with systolic and DBP and MAP were obtained in the

286 cortical GM and for DBP and MAP in total GM (Table 3). *Kⁱ* versus SBP yielded a positive

287 trend towards significance in total GM. No significant relations were found for SBP, DBP and

288 MAP with K_i in WM and deep GM. For v_p , no significant relations were found with blood

289 pressure measures.

290 The scatterplots in Figure 1 show the relation between K_i and MAP in the four ROIs in more

291 detail. Supplemental Figure 1 illustrates the relation between v_p and MAP in the four ROIs.

292

293 *Cardiovascular risk factors*

294 The obtained relations between K_i and DBP, and K_i and MAP remained significant after alternately adjusting for cardiovascular risk factors, medication intake and cSVD score. When considering BMI, alcohol intake, and cSVD score in the regression analyses with SBP in the cortical GM, the adjusted relations did not remain significant, but still showed a positive trend towards significance (β = 0.216, *P* = 0.062, β = 0.245, *P* = 0.053 and β = 0.245, *P =* 0.059, respectively). For total GM, the relation was found to be significant when correcting for 300 history of smoking or intake of cholesterol medication (β = 0.231, *P* = 0.050 and β = 0.233, *P =* 0.049, respectively).

302

Subgroup analyses

Discussion

 In this study, we set out to investigate the relationship between hypertension, SBP, DBP and MAP, and BBB leakage measured with a highly sensitive DCE-protocol at 7 Tesla MRI in human subjects. Based on dichotomous hypertension status, we found no relation with BBB leakage. For the individual blood pressure characteristics, i.e., SBP, DBP and MAP, a higher blood pressure was associated with stronger BBB leakage in the grey matter and not in the white matter. The results were independent of cardiovascular risk factors and presence of cSVD imaging markers. Medically well treated patients (NT+) showed less BBB leakage than patients with current hypertension (pooled HT- and HT+ group).

 The BBB is often assumed to become impaired due to the pathophysiological pathway as a 325 consequence of hypertension.^{2,6} To investigate whether increased blood pressure impacts the BBB integrity prior to the presence of overt cerebral tissue damage, this research focused on differences in BBB leakage between hypertensive patients with no known cerebrovascular disease and normotensive controls. The lack of differences in BBB leakage found between the

 hypertensive and normotensive group, is likely due to the similarities of the blood pressure characteristics of the two groups. SBP was the only blood pressure measure found to be higher in the hypertensive patients. In addition to the groups being matched beforehand on age and sex, the other cardiovascular risk factors, blood measures, and cSVD scores were also found to be similar across the two groups. However, we observed a large variation in BBB 334 leakage in the hypertensive patients $(NT+, HT-$, and $HT+$), which also could explain the absence of a difference in BBB leakage between the hypertension versus normotension group. This demonstrates a large influence of current blood pressure (as opposed to hypertension status) on the BBB integrity. The observed relation between current blood pressure and BBB leakage suggests that a higher blood pressure could lead to endothelial dysfunction, impairing the permeability of the barrier.

 In the GM, a positive relation between blood pressure and BBB leakage was obtained. In contrast, no relation was obtained within the WM. Our findings imply that in grey matter, especially in the well perfused cortical grey matter, subtle leakage is easier, and therefore earlier, to detect than in the less perfused white matter. Additionally, the tissue around the basal ganglia, thus WM, is more protected from the effects of cerebrovascular dysfunction as these arterioles contain two layers, whereas the superficial perforating arterioles have only 347 one layer.

 Previous studies using hypertension models in animals showed that a higher BBB 350 permeability is related to hypertension^{6,21,22}, although some studies did not find any 351 differences in hypertensive animal models.^{23,24} It should be noted that these studies use different methods of measuring BBB leakage, as they use other contrast agents, such as 353 fluorescently labeled dextran or lectin.^{21,22,25} Furthermore, these studies are able to dissect the

 brain after imaging, to investigate the neurovascular properties in more detail. Studies on BBB leakage in humans often focus on diagnosed cerebrovascular diseases, such as cSVD 356 and (mixed) dementia.^{8,9,26,27} These studies demonstrated stronger BBB leakage in these patients, and showed that hypertension is a significant covariate. However, they did not investigate hypertension as a separate condition, or in subjects without overt neurovascular disease.

 The associations with blood plasma volume fraction were contrary to the findings of the leakage rate in this study. Differences in blood plasma volume fraction were found in hypertensive patients versus normotensive controls, based on dichotomous status, while no relations were found for the current blood pressure measures. These results are contradictory to the pathway of a reduced cerebral blood flow, which is related to the blood plasma volume fraction, in hypertension. However, the higher blood plasma volume in hypertensive patients is not indicative of an advanced cerebrovascular disease stage, as vessels tend to narrow 367 (lower blood volume or flow) in a more advanced hypertensive disease state.²⁸

As previous studies showed an association between age and sex, and BBB leakage, we

370 initially adjusted for these two covariates. $31-33$ We indeed found a strong correlation between

sex and leakage measures, indicating that women have a lower BBB permeability compared

to men. This effect could be explained by the hormonal differences between men and women,

373 as female hormones, such as estrogen, may act neuroprotective. $32,33$

Cardiovascular risk factors

This study assessed several cardiovascular risk factors, as well as a cSVD score which was

377 rated on a scale based on previous literature and reflects the total cSVD burden.^{14,29} All

observed associations remained significant after adjusting for these covariates. In contrast to

379 our findings, previous studies showed that cSVD was associated with higher BBB leakage.^{8,30} The low number of cSVD markers observed in our population compared to the more severe cSVD rates in other studies could account for this divergence. We therefore emphasize that in this study, we set out to measure this specific consequence of microvascular damage in a rather early stage of (or mild) cSVD. *Hypertension subgroups* As mentioned above, our results show a large effect on the BBB leakage rate of the actual blood pressure, measured preceding the MRI examination, rather than hypertension status. While comparing the leakage rates between the hypertensive subgroups, a trend of stronger BBB leakage was found in hypertensive patients with inadequate antihypertensive medication 390 ($HT+$), compared to patients with effective antihypertensive medication ($NT+$). The HT-391 group tends to be associated with higher BBB leakage values than the $NT+$ group, but only slightly lower values than the HT+ group. As the HT+ group does not show significantly higher or lower values than the HT- group, and the combined HT group obtained higher leakage values than the NT+ group, we suggest that effective medication has a protective effect on BBB permeability. Previous studies also have shown such restoring effects of 396 specific antihypertensive medication in hypertensive rat models.⁶ However, it is important to

be aware of the small sample size of the subgroups.

Strengths and limitations

 This study focused on BBB leakage in patients with high blood pressure, without known cerebrovascular diseases, compared to normotensive controls. The strength of this study design is that it enabled the investigation of early BBB changes, before neurovascular damage is visible on the MRI scans and before subjects experience neurological complaints.

 Furthermore, a sparsely sampled, interleaved MRI protocol was used to obtain subtle BBB measures, which shortened the scanning time substantially compared to frequently used DCE sequences lasting up to 30 minutes. This protocol also allows for other imaging sequences to be scanned in between, allowing to use the scanning time more efficient. Furthermore, using high-field 7T MRI enhances the signal-to-noise ratio with increasing spatial resolution, thereby enabling improved measurement of subtle BBB leakage. There are several methodological considerations. The blood pressure was measured using a 30-minute during automatic protocol, although the most accurate method would be 24-hour ambulatory blood pressure monitoring. Regardless, the blood pressure measurement protocol 413 in this study is validated to be the second most accurate method.³⁴ As discussed, the cSVD scores were relatively low in our population. Future studies should also include participants with higher cSVD scores to improve the ability of investigating BBB leakage in patients with hypertension with varying amounts of visibly developed neurovascular disease. Larger sample sizes in the three hypertension subgroups, or a longitudinal study design (before and after start of antihypertensive treatment) would also be recommended in future research that focuses on studying medication effects on BBB leakage in more detail. While previous studies show varying effects between the different types of antihypertensive medication, our study did not have enough power in the subgroups to draw definite conclusions, as our study was not designed for this specific aim. *Perspectives* To summarize, this study aimed to investigate the relationship between BBB integrity, high

blood pressure and hypertension. For the dichotomous hypertension status, no significant

effects of BBB leakage were found. However, when looking at continuous blood pressure

References

- 1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat. Rev. Nephrol.* 2020;16:223–237.
- 2. Faraco G, Iadecola C. Hypertension: A Harbinger of Stroke and Dementia.
- *Hypertension*. 2013;62:810–817.
- 3. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H,
- Knopman DS, Launer LJ, et al. Impact of Hypertension on Cognitive Function: A
- Scientific Statement From the American Heart Association. *Hypertension*. 2016;68.
- 4. Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease. *Cerebrovasc. Dis.* 2016;42:255–262.
- 5. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiol. Rev.* 2019;99:21–78.
- 6. Katsi V, Marketou M, Maragkoudakis S, Didagelos M, Charalambous G, Parthenakis F,
- Tsioufis C, Tousoulis D. Blood–brain barrier dysfunction: the undervalued frontier of hypertension. *J. Hum. Hypertens.* 2020;34:682–691.
- 7. Canjels LPW, Jansen JFA, Alers RJ, Ghossein‐Doha C, Van Den Kerkhof M, Schiffer
- VMMM, Mulder E, Gerretsen SC, Aldenkamp AP, Hurks PPM, et al. Blood–brain
- barrier leakage years after pre‐eclampsia: dynamic contrast‐enhanced 7‐TESLA MRI
- study. *Ultrasound Obstet. Gynecol.* 2022;60:541–548.
- 8. Thrippleton MJ, Backes WH, Sourbron S, Ingrisch M, van Osch MJP, Dichgans M, Fazekas F, Ropele S, Frayne R, van Oostenbrugge RJ, et al. Quantifying blood-brain

Alzheimers Dement. 2019;15:840–858.

- Gnedovskaya EV, Krotenkova MV. Daily blood pressure profile and blood–brain barrier
- permeability in patients with cerebral small vessel disease. *Sci. Rep.* 2022;12:7723.
- 10. Raja R, Rosenberg GA, Caprihan A. MRI measurements of Blood-Brain Barrier

function in dementia: A review of recent studies. *Neuropharmacology*. 2018;134:259–

271.

11. Kerkhof M, Voorter PHM, Canjels LPW, Jong JJA, Oostenbrugge RJ, Kroon AA,

Jansen JFA, Backes WH. Time‐efficient measurement of subtle blood–brain barrier

 leakage using a T ¹ mapping MRI protocol at 7 T. *Magn. Reson. Med.* 2021;85:2761– 2770.

 12. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. Whole Brain Segmentation. *Neuron*. 2002;33:341–355.

 13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. *J. Cereb. Blood Flow Metab.* 1983;3:1–7.

 14. Staals J, Makin SDJ, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology*. 2014;83:1228– 1234.

- 15. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at
- 1.5 T in Alzheimer's dementia and normal aging. *Am. J. Roentgenol.* 1987;149:351–356.
- 16. Klarenbeek P, van Oostenbrugge RJ, Rouhl RPW, Knottnerus ILH, Staals J. Ambulatory
- Blood Pressure in Patients With Lacunar Stroke: Association With Total MRI Burden of
- Cerebral Small Vessel Disease. *Stroke*. 2013;44:2995–2999.
- 17. Wardlaw JM, Benveniste H, Nedergaard M, Zlokovic BV, Mestre H, Lee H, Doubal FN,
- Brown R, Ramirez J, MacIntosh BJ, et al. Perivascular spaces in the brain: anatomy,
- physiology and pathology. *Nat. Rev. Neurol.* 2020;16:137–153.
- 18. Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis. *Int. J. Stroke*. 2019;14:359–371.
- 19. Kerkhof M van den, Thiel MM van der, Oostenbrugge RJ van, Postma AA, Kroon AA,
- Backes WH, Jansen JF. Impaired damping of cerebral blood flow velocity pulsatility is
- associated with the number of perivascular spaces as measured with 7T MRI. *J. Cereb.*
- *Blood Flow Metab.* 0:0271678X231153374.
- 20. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol.* 2013;12:483–497.
- 21. Santisteban MM, Iadecola C, Carnevale D. Hypertension, Neurovascular Dysfunction, and Cognitive Impairment. *Hypertension*. 2023;80:22–34.
- 22. Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating Angiotensin II Gains Access to the Hypothalamus and Brain Stem During Hypertension via Breakdown of the Blood–Brain Barrier. *Hypertension*. 2014;63:572–579.

23. Naessens DMP, De Vos J, VanBavel E, Bakker ENTP. Blood–brain and blood–

cerebrovascular disease with DCE-MRI: Test-retest reproducibility and its influencing

- 2017;46:159–166.
- 31. Verheggen ICM, De Jong JJA, Van Boxtel MPJ, Gronenschild EHBM, Palm WM,
- Postma AA, Jansen JFA, Verhey FRJ, Backes WH. Increase in blood–brain barrier
- leakage in healthy, older adults. *GeroScience*. 2020;42:1183–1193.
- 32. Weber CM, Clyne AM. Sex differences in the blood–brain barrier and
- neurodegenerative diseases. *APL Bioeng.* 2021;5:011509.
- 33. Dion-Albert L, Bandeira Binder L, Daigle B, Hong-Minh A, Lebel M, Menard C. Sex
- differences in the blood–brain barrier: Implications for mental health. *Front.*
- *Neuroendocrinol.* 2022;65:100989.
- 34. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,
- Coca A, De Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the
- management of arterial hypertension. *Eur. Heart J.* 2018;39:3021–3104.
-
-
-
-
-
-
-
-
-
-
-

Figure legends

- 589 Table 1: Characteristics of hypertensive patients and normotensive control participants.
- 590 Significant differences are depicted in bold.
- 591

All rights reserved. No reuse allowed without permission.

592 *ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; PVS,

593 perivascular spaces; BG, basal ganglia; CSO, centrum semiovale; cSVD, cerebral small vessel 594 disease.

595

- 596 Table 2: Comparison of K_i and v_p between hypertensive patients and normative control participants, obtained by regression analysis adjusted for
- 597 age and sex. Significant differences are depicted in bold.
- 598 *BBB indicates blood-brain barrier; MAP, mean arterial pressure; *Ki*, blood-brain barrier leakage; *vp*, blood plasma volume fraction; WM, white
- 599 matter; GM, grey matter.

 K_i (*10⁻⁴)

 $v_p(^{*}10^{2})$

- 600 Table 3: Multivariable linear regression analyses were performed to obtain the association
- 601 between BBB leakage rate and blood plasma volume fraction, and blood pressure measures,
- 602 adjusted for age and sex. Significant differences are depicted in bold.

603

604 *MAP indicates mean arterial pressure; *Ki*, blood-brain barrier leakage; *vp*, blood plasma

605 volume fraction; WM, white matter; GM, grey matter

All rights reserved. No reuse allowed without permission.

Figure 1: Scatterplots of the blood-brain barrier leakage rate in the four regions of interest versus the mean arterial pressure. The red open and solid data points indicate hypertensive patients without (HT-) and with intake of antihypertensive medication (HT+), respectively, and the blue open and solid data points indicate normotensive participants without (NT-) and with intake of antihypertensive medication (NT+), respectively. * indicates significant associations. Note that the regression line aims to improve visualization, as it is not corrected for age and sex.

Figure 2. Blood-brain barrier (BBB) leakage in the cortex for the three hypertensive patient subgroups. NT+ indicates normotensive participants with intake of antihypertensive medication, HT- and HT+ hypertensive patients without and with intake of antihypertensive medication, respectively. A trend can be observed between the NT+ and the HT+ group. Note that the combined HT- and HT+ group shows a significant difference with NT+ group.